A phase II, randomized, open-label study to assess the efficacy, safety, and pharmacokinetics (PK) of maintenance cabozantinib (XL184) plus best supportive care (BSC) versus BSC in children, adolescents and young adults (AYA) with unresectable residual osteosarcoma either at diagnosis or at first relapse after standard treatment. - CLIN-60000-461

Ipsen Innovation0 个研究点目标入组 71 人开始时间: 2024年2月15日最近更新: 2024年7月22日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Ipsen Innovation
入组人数: 71

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 0 至 64（—）
性别: All

入选标准

•Participants must be =5 and =30 years of age at the time of study entry., Adequate organ and marrow function., Adequately controlled blood pressure (BP) with or without antihypertensive medications, Male and/or female (according to their reproductive organs and functions assigned by chromosomal complement). (FDA 2016), Contraception and barriers as well as pregnancy testing is required as appropriate for the age and sexual activity of pediatric participants and as required by local regulations., All participants (typically =18 years) and/or their parents or legal guardians must sign a written informed consent and assent must be obtained from minor participants according to local guidelines., Histologically or cytologically confirmed diagnosis of high-grade osteosarcoma as defined by a local pathologist, Participants with unresectable residual disease after standard chemotherapy treatment at diagnosis or first relapse (treated with systemic chemotherapy). A minimum of 4 cycles of systemic chemotherapy (or minimum of 2 cycles if chemotherapy was stopped early due to toxicity) must have been received, Measurable residual or evaluable disease by RECIST version 1.1. Participants will be considered with evaluable disease if they have only non-measurable disease as per RECIST version 1.1 criteria., Absence of PD (defined by the investigator according to RECIST version 1.1) at study entry. Note, the two most recent radiological evaluations (e.g. computerised tomography (CT) or magnetic resonance resonance imaging (MRI) scan) including the one following completion of chemotherapy should be available later to facilitate BIRC review., Chemotherapy must be the last anticancer treatment received by participants before study entry and must have been completed at least 4 weeks but no longer than 2 months before randomization., Participants must have recovered to Grade =1, except for alopecia, ototoxicity, and Grade =2 peripheral neuropathy, per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0) from the acute toxic effects of all prior anticancer therapy at study entry, unless AEs are clinically non significant and/or stable on supportive therapy, per investigator clinical judgment., Life expectancy >6 months., Performance level: participants must have a Lansky or Karnofsky performance status score of =70 corresponding to ECOG categories 0-1.

排除标准

•Low grade osteosarcoma and periosteal osteosarcoma, Any other active malignancy at time of first dose of study intervention or diagnosis of another malignancy within 3 years prior to first dose of study intervention that requires active treatment., Pregnancy or breast-feeding., Participants who in the opinion of the investigator may not be able to comply with the requirements of the study are not eligible, Major surgery (eg, orthopaedic surgery, removal or biopsy of brain metastasis) within 8 weeks before randomization. Complete wound healing from major surgery must have occurred 4 weeks before randomization and from minor surgery (eg, simple excision, tooth extraction) at least 10 days before randomization. Participants with clinically relevant ongoing complications from prior surgery are not eligible., Previous treatment with cabozantinib or another MET/hepatocyte growth factor (HGF) inhibitor (e.g., tivantinib, crizotinib)., Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks or 5 half-lives of the agent, whichever is longer, before first dose of study intervention., Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study intervention (or washout of at least 5 half-lives, whichever is shorter)., Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery or major surgery e.g., removal or biopsy of brain metastasis) and stable for at least 4 weeks prior to randomization. Eligible participants must be neurologically asymptomatic and without systemic corticosteroid treatment at the time of randomization. Note: Participants with a known seizure disorder who are receiving non-enzyme inducing anticonvulsants and have well-controlled seizures on a stable dose of anti-convulsant may be enrolled., Participants who have an uncontrolled/active infection requiring systemic therapy., Participants who are unable to swallow intact tablets., Participants with uncontrolled, significant intercurrent or recent illness., Previously identified allergy or hypersensitivity to components of the study treatment formulations.

研究者

发起方

Ipsen Innovation

相似试验

进行中（未招募）

1 期

EUCTR2009-012460-14-GBGlaxoSmithKline Biologicals376

进行中（未招募）

1 期

EUCTR2009-012460-14-NLGlaxoSmithKline Biologicals376

进行中（未招募）

1 期

EUCTR2009-012460-14-BEGlaxoSmithKline Biologicals376

进行中（未招募）

1 期

Multicenter Clinical Trial in subjects with HER2-negative primary tumors. The subjects will be evaluated for the presence of HER2 positive Circulating Tumor Cells (CTCs) in blood. In case of at least one HER2-positive CTC in blood, the subject will be randomized to receive either (nabTM)-paclitaxel + trastuzumab (ARM A) or (nabTM)-paclitaxel (ARM B).Metastatic Breast Cancer in HER2- positive CTC with primary HER2-negative.MedDRA version: 16.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864

EUCTR2012-005352-41-ITAZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI CREMONA86

进行中（未招募）

不适用

A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX6 + Cetuximab versus FOLFIRI + Cetuximab as first-line therapy in patients with metastatic colorectal cancer

EUCTR2004-002391-42-HUCECOG (Central European Cooperative Oncology Group)150